Find The Stupid In This



Intensified Chemotherapy Shows Promise for Children With Very High Risk Form of Leukemia

Dec. 10, 2012 — Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children’s Hospital Cancer Center in Boston.

The trial leaders will present the results of the Dana-Farber Cancer Institute ALL Consortium study, which involved nearly 500 patients under age 18 with B-precursor acute lymphoblastic leukemia (B-ALL), at the annual meeting of the American Society of Hematology (ASH) conference.

Trial participants received an initial course of “induction” chemotherapy for B-ALL, a cancer of the blood that is one of the most common cancers in children below age 15. After a month of treatment, the patients had a bone marrow sample sent for a test able to measure levels of leukemia that cannot be seen under a microscope. Thirty-five of the patients were deemed to have a very high risk of relapsing because they retained relatively large numbers of leukemia cells as measured by this test. An additional 16 patients were also considered very high-risk because their leukemia cells had certain chromosomal abnormalities.

These 51 patients then received an intensified treatment regimen consisting of two additional rounds of chemotherapy using agents not typically given to newly diagnosed patients with B-ALL. This was followed by an intensified consolidation phase of therapy to keep the disease in remission, and then a standard maintenance phase to further deter the disease from returning.

Investigators estimate that, five years after reaching complete remission, the rate of event-free survival (a measure of survival without relapse or development of another cancer) was 76 percent for these very high-risk patients. By contrast, less than half of similar patients who receive standard chemotherapy reach the five-year mark without relapsing.

“Pediatric patients with B-ALL traditionally receive a standard course of chemotherapy if their risk of relapse is low, and a slightly intensified course if their risk is higher,” says the study’s lead author, Lynda Vrooman, MD, of Dana-Farber/Children’s Hospital Cancer Center. “In this study, we identified a new risk group — those with a very high risk of relapse — and studied the effect of a novel, even more intensive chemotherapy regimen on their outcome.”

“Though it involved a relatively small number of patients, the new trial is one of the first to show improved outcomes for this set of patients as a result of an intensified chemotherapy protocol,” says senior author Lewis Silverman, MD, of Dana-Farber/Children’s Hospital Cancer Center. Trial leaders will continue to track the study participants to gauge the durability of the remissions produced by the intensified treatment.

Co-authors of the study include Kristen Stevenson, MS, and Donna Neuberg, ScD, of Dana-Farber; Marian Harris, MD, of Boston Children’s Hospital; and Stephen Sallan, MD, of Dana-Farber/Children’s Hospital Cancer Center.

Related Stories
Gene Responsible for Relapses in Young Leukemia Patients (Oct. 26, 2011) — One of the causes of resistance to cancer treatment in children is now beginning to be elucidated. Acute lymphoblastic leukemia patients with a particular form of the ATF5 gene are at higher risk of …  > read more

Stem Cell Treatment Is Effective for Certain Cases of Acute Leukemia (Dec. 13, 2010) — Some adults and children with acute leukemia could benefit from certain transplants of blood stem cells, but the benefits are not equal across all cases of leukemia, according to a new review of 15 …  > read more

Way to Overcome Radiation Resistance in Leukemia Discovered (Sep. 29, 2010) — Radiation resistance in leukemia can be overcome by selectively attacking a molecular target known as SYK tyrosine kinase, according to new …  > read more

Milk Thistle Herb Protects Cancer Patients from Chemotherapy-Associated Liver Toxicity (Dec. 27, 2009) — A new study finds that the herb milk thistle may help treat liver inflammation in cancer patients who receive chemotherapy. The study indicates that the herb could allow patients to take potent doses …  > read more

New Knowledge About Bone Marrow Transplants Can Help Leukemia Patients (Oct. 1, 2009) — Acute lymphatic leukemia is the most common form of blood cancer in children. Even though chemotherapy is improving, the cancer often returns. New research shows that cancer cells that have been …  > read more–+Top+Health%29


Next Post

Fluorosilicic Acid ~ In ONE Paragraph ...

Thu Dec 13 , 2012
“Fluorosilicic Acid… is an aqueous solution… used for the Fluoridation of drinking water… Fluorosilicic Acid is the most widely used fluoridation agent in Australia, and has several advantages over powdered fluoridation products, including the elimination of manual handling, dust control, and slurrification.[1]  Fluorosilicic acid is aparticularly aggressive and hazardous chemical and requires specific […]

You May Like